Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (141-150 of 209) with videos related to

Pageof 21
Sort By:
Dermatology and Therapy|July 8, 2021
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area ScoreKim A Papp, Mark G Lebwohl, Leon H Kircik, et al.
Journal of the American Academy of Dermatology|March 4, 2023
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 studyBoni E Elewski, Mark G Lebwohl, Milan J Anadkat, et al.
Journal of the American Academy of Dermatology|January 1, 2026
Clarifying Psoriasis Disease Severity: A Position Statement from the National Psoriasis Foundation Medical BoardAndrew Blauvelt, Ronald Prussick, Joseph F Merola, et al.
Journal of the American Academy of Dermatology|April 19, 2011
A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticumJane Y Yoo, Robin R Blum, Giselle K Singer, et al.
Journal of the American Academy of Dermatology|October 8, 2017
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trialsMark G Lebwohl, Kim A Papp, Lauren B Marangell, et al.
Nature Reviews. Disease Primers|November 25, 2016
PsoriasisJacqueline E Greb, Ari M Goldminz, James T Elder, et al.
Journal of the American Academy of Dermatology|March 1, 2014
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis SurveyMark G Lebwohl, Hervé Bachelez, Jonathan Barker, et al.
Dermatology and Therapy|December 19, 2025
Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During TreatmentMark G Lebwohl, Darrell S Rigel, Zeynep Eroglu, et al.
Dermatology and Therapy|November 26, 2024
Brodalumab: Six-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 9, 2024
Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasisA David Burden, Robert Bissonnette, Milena Anatchkova, et al.
Pageof 21

Showing results (141-150 of 209) with videos related to

Sort By:
Pageof 21
Dermatology and Therapy|July 8, 2021
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area ScoreKim A Papp, Mark G Lebwohl, Leon H Kircik, et al.
Journal of the American Academy of Dermatology|March 4, 2023
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 studyBoni E Elewski, Mark G Lebwohl, Milan J Anadkat, et al.
Journal of the American Academy of Dermatology|January 1, 2026
Clarifying Psoriasis Disease Severity: A Position Statement from the National Psoriasis Foundation Medical BoardAndrew Blauvelt, Ronald Prussick, Joseph F Merola, et al.
Journal of the American Academy of Dermatology|April 19, 2011
A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticumJane Y Yoo, Robin R Blum, Giselle K Singer, et al.
Journal of the American Academy of Dermatology|October 8, 2017
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trialsMark G Lebwohl, Kim A Papp, Lauren B Marangell, et al.
Nature Reviews. Disease Primers|November 25, 2016
PsoriasisJacqueline E Greb, Ari M Goldminz, James T Elder, et al.
Journal of the American Academy of Dermatology|March 1, 2014
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis SurveyMark G Lebwohl, Hervé Bachelez, Jonathan Barker, et al.
Dermatology and Therapy|December 19, 2025
Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During TreatmentMark G Lebwohl, Darrell S Rigel, Zeynep Eroglu, et al.
Dermatology and Therapy|November 26, 2024
Brodalumab: Six-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 9, 2024
Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasisA David Burden, Robert Bissonnette, Milena Anatchkova, et al.
Pageof 21